Ainos Inc. (AIMD)
NASDAQ (CM) NASDAQ (CM) Primary Summary
AIMD Chart
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities.
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform development From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.
Ainos Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Seneschal Advisors LLC Seneschal Advisors LLC | 1,800 | $6,237 | $3,024 | -$3,213 | -51.52% |
Ainos Inc. (AIMD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ainos Inc. ever had a stock split?
Ainos Inc. Profile
| Biotechnology Industry | Healthcare Sector | Chun-Hsien Tsai CEO | NASDAQ (CM) Exchange | 00902F402 CUSIP |
| US Country | 41 Employees | - Last Dividend | 30 Jun 2025 Last Split | 4 Nov 2013 IPO Date |
Overview
Ainos, Inc. is a healthcare company that has dedicated its efforts towards the advancement of medical technologies specifically designed for point-of-care testing and the provision of safe, novel medical treatments for various disease indications. The enterprise emerged from its previous identity as Amarillo Biosciences, Inc., undergoing a name change to Ainos, Inc. in May 2021, signaling a new phase in its journey. This transformation reflects a broadened scope and ambition in addressing healthcare challenges through innovative solutions. Having been incorporated back in 1984, Ainos has its operational base established in San Diego, California, positioning it well within one of the United States' biotech hotspots, which allows for better integration into the industry's innovative core.
Products and Services
- COVID-19 Antigen Rapid Test Kit and Ainos' Cloud-Based Test Management App: This offering consists of an antigen rapid test kit, a personal application, and an enterprise app. Together, they provide an integrated solution for managing COVID-19 testing at both individual and organizational levels, leveraging cloud technology for efficiency and scalability.
- COVID-19 Nucleic Acid Test: A diagnostic tool designed for the detection of COVID-19, utilizing the sensitivity and specificity advantages of nucleic acid testing methodologies to ensure reliable results.
- Volatile Organic Compounds Point-of-Care Testing: Ainos develops technology for the detection of volatile organic compounds (VOCs) in a point-of-care setting, facilitating the early diagnosis of diseases through non-invasive means.
- Very Low-Dose Oral Interferon Alpha: This involves a low-dose oral formulation of interferon alpha, harnessing IFN-alpha's broad treatment applications in a potentially safer and patient-friendly manner. The approach suggests an innovative path in combating various diseases by modulating the immune response.
- Synthetic RNA: Ainos is also pioneering in the realm of SRNA (Synthetic RNA) technology platform in Taiwan, aiming at harnessing the potential of synthetic RNA in gene editing and therapy, thereby opening new avenues for treatment modalities.
- Additional Offerings: The company's portfolio extends beyond the aforementioned with products aimed at women's health, pneumonia treatment, and the development of unique tools such as the Ainos Pen and AI Nose. These developments signify Ainos' diversified approach towards tackling healthcare challenges with technology-driven solutions.
